{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:17:16Z","timestamp":1789697836989,"version":"4.0.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.expneurol.2014.04.018","type":"journal-article","created":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T21:31:14Z","timestamp":1398979874000},"page":"37-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"PA","title":["Mode of action and clinical studies with alemtuzumab"],"prefix":"10.1016","volume":"262","author":[{"given":"Joanne L.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alasdair J.","family":"Coles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2014.04.018_bb0005","first-page":"1","article-title":"Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis","author":"Azzopardi","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.expneurol.2014.04.018_bb0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.it.2004.11.006","article-title":"The new paradigm of T-cell homeostatic proliferation-induced autoimmunity","volume":"26","author":"Baccala","year":"2005","journal-title":"Trends Immunol."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0015","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/ni.2610","article-title":"T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10","volume":"14","author":"Bandala-Sanchez","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0020","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s12020-010-9405-6","article-title":"Prevalence of incidental thyroid cancer and its ultrasonographic features in subcentimeter thyroid nodules of patients with hyperthyroidism","volume":"39","author":"Berker","year":"2011","journal-title":"Endocrine"},{"issue":"Pt 6","key":"10.1016\/j.expneurol.2014.04.018_bb0025","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/brain\/123.6.1102","article-title":"Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey","volume":"123","author":"Broadley","year":"2000","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.expneurol.2014.04.018_bb0030","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/1352458512444915","article-title":"Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab","volume":"19","author":"Button","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0035","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1084\/jem.192.4.549","article-title":"Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells","volume":"192","author":"Cho","year":"2000","journal-title":"J. Exp. Med."},{"issue":"9856","key":"10.1016\/j.expneurol.2014.04.018_bb0040","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.expneurol.2014.04.018_bb0075","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO;2-#","article-title":"Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis","volume":"46","author":"Coles","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0055","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s00415-005-0934-5","article-title":"The window of therapeutic opportunity in multiple sclerosis","volume":"253","author":"Coles","year":"2005","journal-title":"J. Neurol."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0050","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s00415-005-0934-5","article-title":"The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy","volume":"253","author":"Coles","year":"2006","journal-title":"J. Neurol."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0045","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"Coles","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0060","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1474-4422(11)70020-5","article-title":"Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes","volume":"10","author":"Coles","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0065","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0b013e31824e8ee7","article-title":"Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial","volume":"78","author":"Coles","year":"2012","journal-title":"Neurology"},{"issue":"9856","key":"10.1016\/j.expneurol.2014.04.018_bb0070","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.expneurol.2014.04.018_bb0080","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1136\/jnnp-2011-301993.171","article-title":"129\u2005Serum IL-21 as a biomarker in multiple sclerosis","volume":"83","author":"Cossburn","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.expneurol.2014.04.018_bb0090","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/bjo.84.1.107","article-title":"Campath-1H therapy in refractory ocular inflammatory disease","volume":"84","author":"Dick","year":"2000","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0100","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1600-065X.1996.tb00901.x","article-title":"Organ-specific autoimmunity induced by lymphopenia","volume":"149","author":"Gleeson","year":"1996","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0105","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1084\/jem.192.4.557","article-title":"Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation","volume":"192","author":"Goldrath","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0110","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1212\/WNL.58.2.169","article-title":"Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines","volume":"58","author":"Goodin","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2014.04.018_bb0095","first-page":"74","article-title":"Infection risk with alemtuzumab in patients with relapsing remitting multiple sclerosis: pooled results from the CARE-MS I and CARE-MS II trials","volume":"19","author":"Havrdova","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0115","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1034\/j.1600-0404.2000.101001036.x","article-title":"Autoimmune diseases in families of French patients with multiple sclerosis","volume":"101","author":"Heinzlef","year":"2000","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0120","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/jnnp-2011-300826","article-title":"Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis","volume":"83","author":"Hill-Cawthorne","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.expneurol.2014.04.018_bb0130","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1365-2567.2009.03115.x","article-title":"Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model","volume":"128","author":"Hu","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.expneurol.2014.04.018_bb0135","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1136\/bjo.79.11.1054","article-title":"Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H","volume":"79","author":"Isaacs","year":"1995","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0140","first-page":"1103","article-title":"Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H","volume":"23","author":"Isaacs","year":"1996","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0145","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/rheumatology\/35.3.231","article-title":"CAMPATH-1H in rheumatoid arthritis\u2014an intravenous dose-ranging study","volume":"35","author":"Isaacs","year":"1996","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0160","first-page":"2052","article-title":"IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)","volume":"119","author":"Jones","year":"2009","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0155","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1093\/brain\/awq176","article-title":"Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity","volume":"133","author":"Jones","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2014.04.018_bb0165","doi-asserted-by":"crossref","first-page":"20200","DOI":"10.1073\/pnas.1313654110","article-title":"Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation","volume":"110","author":"Jones","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0170","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.expneurol.2014.04.018_bb0175","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1084\/jem.20021812","article-title":"Involvement of avidity for major histocompatibility complex in homeostasis of naive and memory T cells","volume":"197","author":"Kassiotis","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0180","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.imlet.2004.10.022","article-title":"A causal link between lymphopenia and autoimmunity","volume":"98","author":"Khoruts","year":"2005","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0185","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1365-2265.2004.02043.x","article-title":"Ultrasonographic screening for detection of thyroid cancer in patients with Graves' disease","volume":"60","author":"Kim","year":"2004","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0190","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0092-8674(04)00335-6","article-title":"Homeostatic expansion of T cells during immune insufficiency generates autoimmunity","volume":"117","author":"King","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.expneurol.2014.04.018_bb0195","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1046\/j.1365-2168.2000.01504.x","article-title":"Multicentre study of thyroid nodules in patients with Graves' disease","volume":"87","author":"Kraimps","year":"2000","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0200","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.clim.2006.04.569","article-title":"Autoimmunity during lymphopenia: a two-hit model","volume":"120","author":"Krupica","year":"2006","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0205","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple-sclerosis\u2014an Expanded Disability Status Scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2014.04.018_bb0210","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/rheumatology\/keg424","article-title":"Remission induction in Behcet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H","volume":"42","author":"Lockwood","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.expneurol.2014.04.018_bb0150","first-page":"74","article-title":"Adverse event profile of alemtuzumab in active relapsing remitting multiple sclerosis patients who participated in the CARE-MS studies: three-year follow-up","volume":"19","author":"Lycke","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0215","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1212\/WNL.0b013e3182a35215","article-title":"Immune competence after alemtuzumab treatment of multiple sclerosis","volume":"81","author":"McCarthy","year":"2013","journal-title":"Neurology"},{"issue":"Pt 1","key":"10.1016\/j.expneurol.2014.04.018_bb0220","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/brain\/119.1.225","article-title":"Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis","volume":"119","author":"Moreau","year":"1996","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2014.04.018_bb0225","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.4049\/jimmunol.180.6.3910","article-title":"Homeostatic proliferation of lymphocytes results in augmented memory-like function and accelerated allograft rejection","volume":"180","author":"Moxham","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0230","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.4049\/jimmunol.165.4.1733","article-title":"Cutting edge: naive T cells masquerading as memory cells","volume":"165","author":"Murali-Krishna","year":"2000","journal-title":"J. Immunol."},{"issue":"Pt 5","key":"10.1016\/j.expneurol.2014.04.018_bb0235","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/eye.1995.140","article-title":"Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H","volume":"9","author":"Newman","year":"1995","journal-title":"Eye Lond."},{"issue":"1","key":"10.1016\/j.expneurol.2014.04.018_bb0240","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10875-009-9327-3","article-title":"B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis","volume":"30","author":"Thompson","year":"2010","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0245","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1172\/JCI119110","article-title":"Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a\/CD18 (LFA-1) on NK cells","volume":"98","author":"Wing","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0250","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm965","article-title":"Homeostatic proliferation is a barrier to transplantation tolerance","volume":"10","author":"Wu","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0085","first-page":"74","article-title":"Detection, incidence and management of glomerulonephritis in the alemtuzumab clinical development programme","volume":"19","author":"Wynn","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.expneurol.2014.04.018_bb0255","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1568-9972(02)00086-1","article-title":"HIV and autoimmunity","volume":"1","author":"Zandman-Goddard","year":"2002","journal-title":"Autoimmun. Rev."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488614001204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488614001204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T21:59:22Z","timestamp":1565387962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488614001204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":50,"alternative-id":["S0014488614001204"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2014.04.018","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mode of action and clinical studies with alemtuzumab","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2014.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}